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Introduction
During the drug discovery process, in vitro drug metabolism data are widely used in the pharmaceutical industry as criteria to select new chemical entities for further development (Rodrigues, 1997 ). An important parameter, which is used to rank compounds on the basis of their metabolic stability, is the intrinsic clearance (CL in ), determined using hepatic microsomes (Obach, 1999; McGinnity and Riley, 2001 ).The metabolite formation method has been used for measurement of in vitro CL in (Madan et al., 2002; Jones and Houston, 2004) . Here, the initial rate of metabolite production is measured using hepatic microsomes over a range of substrate concentrations under linear conditions with respect to protein concentration and time (Houston and Galetin, 2003) .
Alternatively, the substrate depletion approach has been adopted, where the consumption of the parent drug is monitored over time (Obach, 1999) . This method is particularly popular in the pharmaceutical industry, as formal kinetic characterization of the enzymes involved and quantification of metabolites formed are not required, allowing rapid screening of compounds with automated and semi-automated methodologies. Normally at least 20% of the substrate must be metabolized within the incubation period, so that any substrate depletion can be distinguished from baseline variability (Jones and Houston, 2004) . For this reason higher microsome concentrations and longer incubation times are used than in studies utilizing the metabolite formation approach.
Many drugs are lipophilic organic compounds that can bind non-specifically to the lipid-protein milieu of the microsomal membrane. The result of nonspecific binding is a reduction in the free concentration of drug that is available for interaction with This article has not been copyedited and formatted. The final version may differ from this version. microsomal drug metabolizing enzymes. Depletion of unbound drug by extensive membrane partitioning leads to an underestimation of CL in . The "true" CL in , i.e. the value that would be observed in the absence of binding to microsomes, is termed unbound intrinsic clearance (CL in,u ) .
Unbound intrinsic clearance can be calculated by determining the free fraction of compound in microsomal incubations (f u ) according to the relationship:
CL in,u = CL in /f u equation 1
Three different experimental methods are commonly used to determine f u and consequently CL in,u , namely equilibrium dialysis, ultracentrifugation and ultrafiltration.
Of these, equilibrium dialysis is the most widely used method to determine f u as it is experimentally easy and can be performed in a 96 well format (Kariv et al., 2001) . In all three methodologies there is the possibility that nonspecific drug adsorption to equipment surfaces (dialysis membrane, ultrafiltration device, etc.) may distort the values obtained, leading to an underestimation of the CL in,u (Lin et al., 1987) . In addition, these methods are relatively laborious and time-consuming. The aim of the present work was to establish a methodology for the direct determination of CL in,u , without the need for separate measurement of f u . The new method is based on the assumption that compounds bind to or partition into microsomes in a nonspecific fashion, i.e. with low affinity, and that binding sites are not saturated at the concentrations used in microsomal stability assays. Under these conditions, the CL in,u and f u can be directly extrapolated from the microsomal stability data obtained at different microsome concentrations. The method was validated using a series of structurally diverse compounds that are subject to This article has not been copyedited and formatted. The final version may differ from this version. buffer using a 96 well DispoDialyzer (Harvard Apparatus, Holliston, MA). The dialyzing unit consists of two chambers separated by an ultra-thin membrane with a molecular weight cut-off of 10 kDa. The plate was rotated for 12 h at 37° C in the perpendicular direction of the well orientation to ensure a constant contact between the two chambers, The second model (Austin et al., 2002) treats microsomal binding as a non-saturable phase equilibrium process governed by a membrane partition coefficient K P :
Mathematically, this model is equivalent to the particular case of the defined binding site model where binding is non saturable, i.e. F << K D .
In this case, B = (B max /K D ) x F, with K P = B max /K D .
It should be noted that the membrane partition coefficient K P defined in this way is directly proportional to the total number of membrane binding sites and subsequently to the total membrane protein concentration M, i.e.
with K' denoting the proportionality constant.
As pointed out by Austin and coworkers (Austin et al., 1995) , microsomal binding is normally independent of compound concentration, and saturation does not occur at the The free fraction of drug, f u , is given by:
Substituting equations 8 and 9 into equation 7 and rearranging, we obtain:
If intrinsic clearance is determined in the presence of drug binding to microsomes, the relationship between the observed clearance CL in and the "true" clearance of unbound drug, CL in,u is calculated according to equation 1: In order to investigate whether the results obtained with the LESA method reflected the true CL in,u , the unbound fractions (f u ) of the nine drugs investigated were determined by equilibrium dialysis, ultracentrifugation and ultrafiltration at two different microsome concentrations, 0.2 mg/ml and 1 mg/ml (Table 2 ). For chlorpromazine, f u could not be determined by ultrafiltration, since the compound displayed very low mass balance in this system (see Materials and Methods). CL in,u was then calculated by the conventional method using equation 1 (CL in,u = CL in /f u , Table 3 The methodologies most frequently used (equilibrium dialysis, ultrafiltration and ultracentrifugation) determine CL in,u indirectly via measurement of f u (eq. 1). Equilibrium dialysis (Lin et al., 1987 ) is technically simple, a variety of apparatus are commercially available, and using 96 well plates it is possible to determine the f u of several compounds in a single experiment. However, equilibrium time can be long, and unstable drugs or proteins may degrade during long equilibration times. Drug adsorption to the dialysis membrane or dialysis device tends to be greater than drug adsorption to ultracentrifugation tubes, and recovery of the parent compound is not always quantitative.
Another problem that can increase the error in the measurement of f u by equilibrium dialysis is the potential for volume shift due to the Donnan effect (Lin et al., 1987) .
However, the methodology is widely applied and yields satisfactory results if appropriate controls are included.
This article has not been copyedited and formatted. The final version may differ from this version. Ultrafiltration is faster than equilibrium dialysis, but an increased protein concentration during filtration, as well as a potential decrease in the filter pore size due to protein accumulation may cause errors in the measurement of f u . Ultracentrifugation is not affected by membrane or Donnan effects. However, the technique is of low throughput and potentially subject to artifacts due to surface adsorption and variation of the protein concentration during centrifugation.
All the drugs selected for the present study are mainly subject to hepatic oxidative metabolism (Obach, 1999) . Desipramine, amitriptyline, imipramine, verapamil, diltiazem, propafenone, chlorpromazine are basic compounds, midazolam is neutral and diclofenac is acidic. Seven basic compounds were selected because compounds with a pK a > 7.4 generally show greater nonspecific binding than neutral and acidic compounds (Austin et al., 1995) . This is expected because basic compounds exhibit enhanced affinity for membrane phospholipids, as demonstrated by liposome binding studies (Austin et al., 1995; Kramer et al., 1998) . Furthermore, all of the drugs used were reported to display appreciable binding to hepatic microsomes (Obach, 1999) . The substrate depletion approach was used because formal kinetic characterization and metabolite quantification are not required. The CL in was calculated as Dose/AUC ∞ rather than with the more rigorous approach that uses enzyme kinetic data (i.e., maximum enzyme velocity V max and Michaelis-Menten constant K M ). This simplified approach is appropriate, since the substrate concentration employed (1 µM) is below the apparent K M for substrate turnover and no significant product inhibition, or mechanism-based inactivation of the enzyme is present (Obach, 1999) . All the drugs selected were metabolized in HLM with CL in,u ranging between 38 µl/min/mg for diltiazem and 344 µl/min/mg for diclofenac (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. In spite of the experimental issues associated with the traditionally used techniques, the results were in good agreement within the three methods and in comparison with LESA. In addition, the standard errors associated with each method were in the same range for the four methodologies As shown in Table 3 , the values of CL in,u obtained for the different compounds using either experimental determination of f u or the LESA method are comparable.
Austin et al. (Austin et al., 2002 ) measured the CL in and f u for 13 drugs at three different concentrations of rat liver microsomal protein, 0.25, 1 and 4 mg/ml and determined the CL in,u from these data. This set of 13 compounds includes five neutral, four acidic and four basic drugs covering a wide range of lipophilicity. We applied the LESA method to calculate CL in,u from the reported values of CL in (Austin et al., 2002) .
The LESA method could not be applied to isradipine, as only two experimental CL in values were reported (Austin et al., 2002) . As shown in Table 4 , there was a generally good agreement between CL in,u extrapolated by LESA and that calculated using the experimentally measured f u values (Austin et al., 2002) . For 10 out of the 12 compounds analyzed, the difference between the results obtained with the 2 methods was less than 2-fold. The two outliers were amiodarone and astemizole. Both compounds were reported to bind extensively to microsomes even at the lowest concentration tested (0.25 mg/ml), with f u of 0.006 and 0.076 respectively (Austin et al., 2002) , which may introduce a significant error in the calculation of CL in,u by either method. Since CL in,u is the ratio between CL in and f u , compounds with high CL in and very low f u and will yield very high estimates of CL in,u (16000 and 10000 µl/min/mg for amiodarone and astemizole respectively), associated with an amplified statistical error. Obviously, the reciprocal This article has not been copyedited and formatted. The final version may differ from this version. value 1/ CL in,u will be close to zero, posing a practical limit to the applicability of the LESA method. Thus, for amiodarone the extrapolation yielded a negative intercept, which has no physical meaning. On the other hand, extrapolation of the data for astemizole yielded a significantly lower CL in,u than that calculated by the conventional method (Austin et al., 2002) , raising the possibility that the latter was biased by an underestimation of f u for that compound. Further studies will be needed to clarify this The main limitation of LESA is due to the fact that it is utilizing the substrate depletion approach. For this reason, the CL in,u can only be calculated with sufficient accuracy in the case of appreciable turnover of the substrate (at least 20%) (Jones and Houston, 2004) . On the other hand, the CL in,u in LESA is extrapolated linearly from a range of CL in 's obtained at different microsome concentrations. This increases the confidence in the experimental data. Notably, in the other three methodologies, CL in,u is usually obtained from the f u at a single microsome concentration. Another potential limitation of the LESA method is that it is based on the assumption that drug binding to microsomes is truly nonspecific, i.e. of low affinity. The method would not be valid for compounds whose binding is saturated at the concentrations used in the microsomal stability assay. However, as discussed by Austin et al. (Austin et al., 2002) , this is unlikely to occur at the low micromolar concentrations used in modern metabolic assays.
Notwithstanding these potential limitations, the LESA method provides a convenient and rapid method to determine the influence of microsome binding on intrinsic clearance, This article has not been copyedited and formatted. The final version may differ from this version. without the need for separate determination of the unbound fraction. The method should be particularly useful in cases where the unbound fraction cannot be determined by conventional methods due to technical limitations such as nonspecific adsorption to dialysis apparatus or compound solubility (Walsky et al., 2005) . It may also be applicable also to studies of kinetic parameters of drug interaction with microsomal enzymes (e.g. cytochrome P450 inhibition) (Margolis and Obach, 2003; Walsky et al., 2005) and to other in vitro systems, such as hepatocytes, where clearance can be influenced by cellular accumulation (Jones and Houston, 2004) In summary, LESA was shown to accurately determine the CL in,u in the microsomal stability assay by comparison with three traditionally used methods. This article has not been copyedited and formatted. The final version may differ from this version. mg/ml of rat liver microsomes (Austin et al., 2002) .
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